RheaVita

RheaVita markets an innovative continuous freeze-drying technology for (bio)pharmaceutical products, with a manufacturing approach that saves time and money, guarantees product quality, and offers greater operational flexibility compared to traditional batch freeze-drying. RheaVita sells single-vial units for R&D as well as full GMP systems, developing freeze-drying processes quickly with limited product consumption and designing optimal formulations for vaccines and biopharmaceuticals such as mRNA-LNPs, viral vectors and monoclonal antibodies.